Can Gleevec help patients with rheumatoid arthritis?

Imatinib mesylate (Gleevec; Novartis) is often the treatment of choice for individuals with either chronic myelogenous leukemia or gastrointestinal stromal tumors. Now, in a study appearing online on September 14 in advance of publication in the October print issue of the Journal of Clinical Investigation, researchers from Stanford University have shown that imatinib can block the development of disease in a mouse model of rheumatoid arthritis (RA), providing hope of a new treatment for RA.

Although there are two documented cases in which individuals taking imatinib to treat their cancer showed clinical improvement in their RA, there had been no study of the effects of imatinib in a mouse pre-clinical model of RA. So, William Robinson and colleagues administered imatinib to mice with an RA-like disease. Imatinib both prevented the onset of disease and the development of established disease. It did this by inhibiting the function of many of the immune cells that contribute to disease in patients with RA. Importantly, imatinib was also shown to inhibit the proliferation of cells taken from the joints of patients with RA. This study indicates that imatinib might provide relief to the many individuals suffering from RA.


Contact: Karen Honey
Journal of Clinical Investigation

Page: 1

Related biology news :

1. When Gleevec is not enough
2. Single genetic assay could help physicians decide when to switch patients from Gleevec to Sutent
3. Drug that battles resistance to leukemia pill Gleevec extremely effective against cancer
4. A broken stress response system can contribute to Gleevec resistance
5. First report of cancer drug Gleevec as new target therapy for pulmonary hypertension
6. Next-era targeted therapy overcoming Gleevecs shortcomings
7. New drug sidesteps Gleevec resistance in human trials
8. Abnormal fat metabolism underlies heart problems in diabetic patients
9. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
10. Aggressive therapy best for certain AML patients
11. Investigating antibiotic use in acute care patients

Post Your Comments:

(Date:10/9/2015)... Oct. 09 2015 ... of the "Samsung Galaxy S6 Fingerprint ... to their offering. --> http://www.researchandmarkets.com/research/6g9l3b/samsung_galaxy_s6 ... "Samsung Galaxy S6 Fingerprint Sensor - ... offering. --> Research and Markets ...
(Date:10/8/2015)... , Oct. 8, 2015 Synaptics ... human interface solutions, announced today that it will ... fiscal 2016 on Thursday, October 22, 2015, after ... a corresponding conference call for analysts and investors ... which management may discuss forward-looking information.    ...
(Date:10/8/2015)... CITY , 8. Oktober 2015 /PRNewswire/ ... ein global tätiges Unternehmen des Bereiches Tracking, ... Vertrag mit der Gefängnisbehörde Virginias (Department of ... Rahmen elektronische Überwachungsdienste für alle Strafen geliefert ... Derek Cassell , Präsident für den Amerikanischen ...
Breaking Biology News(10 mins):
(Date:10/9/2015)... , Oct. 9, 2015 On October ... the Congressional Record her statement recognizing the third annual ... 11-17. IPAW is sponsored by the Plasma Protein ... is designed to:   , Raise global awareness ... plasma donors in saving and improving lives , ...
(Date:10/9/2015)... Governor Tom Wolf announced today ... on developing T-cell receptor cancer immunotherapy treatments, will create ... expansion project. Pennsylvania , and ... 110 new, high-paying jobs will be created with this ... proposal includes sustained funding for the life science sector ...
(Date:10/9/2015)... HERSHEY, Pa. and ROCKVILLE, ... Therapeutics, Inc. ("ITI"), a privately-held biotechnology company developing ... today announced that it has entered into an ... on LAMP-vax products for the treatment or prevention ... Upon execution of the agreement, Immunomic Therapeutics will ...
(Date:10/9/2015)... , Oct. 9, 2015  DePuy Synthes Trauma* announced ... with Q-PACK ®  Technology**, the only pre-hydrated demineralized ... extremity procedures (foot and ankle, hand and wrist), including ... made here at the 2015 Orthopaedic Trauma Association (OTA) ... natural scaffold for new bone growth) and osteoinductive 2,3 ...
Breaking Biology Technology:
Cached News: